Study Evaluation Tazocin Intervention

Wyeth

Status and phase: Completed; Phase 4

Conditions: Bacterial Infections

Treatments: Drug: Tazocin (pipercillin/tazobactam)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00488189

0910X-102370

Details and patient eligibility

About

This is an antibiotic intervention study to determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.

Enrollment: 134 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients admitted or transferred to ICU/Pulmonary units
• Patients of either sex, 18 years of age or older

Exclusion criteria

• Patients who stay in units less than 48 hours will not be enrolled.

Trial design

Primary purpose: Health Services Research

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

134 participants in 2 patient groups

1

No Intervention group

Description:

baseline, collecting rectal swab samples

2

Active Comparator group

Description:

use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab

Treatment:

Drug: Tazocin (pipercillin/tazobactam)